Biodesix Inc BDSX.OQ BDSX.O is expected to show a rise in quarterly revenue when it reports results on August 7 for the period ending June 30 2025
The Louisville Colorado-based company is expected to report a 3.0% increase in revenue to $18.463 million from $17.93 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Biodesix Inc is for a loss of 7 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Biodesix Inc is $2.00, about 78.9% above its last closing price of $0.42
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.06 | -0.07 | -0.08 | Missed | -17.6 |
Dec. 31 2025 | -0.05 | -0.07 | -0.06 | Beat | 10 |
Sep. 30 2024 | -0.07 | -0.07 | -0.07 | Met | 4.5 |
Jun. 30 2024 | -0.09 | -0.09 | -0.08 | Beat | 13 |
Mar. 31 2024 | -0.14 | -0.14 | -0.14 | Met | 2.3 |
Dec. 31 2023 | -0.10 | -0.11 | -0.10 | Beat | 9.1 |
Sep. 30 2023 | -0.15 | -0.15 | -0.14 | Beat | 6.7 |
Jun. 30 2023 | -0.22 | -0.21 | -0.17 | Beat | 17.7 |
This summary was machine generated August 5 at 21:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)